nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…The individual values for panel A and C are included in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003232#pbio.3003232.s005" target="_blank">S2 Data</a>, Experiment 1, 3 and 4 sheets and <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003232#pbio.3003232.s006" target="_blank">S3 Data</a>, respectively.…”

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. by Peiqi Yin (6533747)

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  by Beatrice T. Nganso (4114768)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. (B) Even though higher proportions of mutualism promote higher richness, introducing this type of interaction into already assembled large communities promotes a sudden drop in richness, while stopping mutualism promotes a slight boost in richness increase. …”

FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)

Average self-reported physical health ratings before or during the COVID-19 pandemic among individuals who engaged during the pandemic in more than 3 (A), 4 (B), or 5 (C) positive... by Elie Mulhem (22537863)

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retr... by Wendy C. Moore (10682686)

“…This study evaluated the real-world impact of mepolizumab treatment in patients with severe asthma over a 4-year follow-up period.</p> <p>This was a retrospective cohort study of patients with asthma initiating mepolizumab (index date: first claim, November 2015–September 2019) using the Merative MarketScan Commercial and Medicare Databases. …”

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)